These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 18024370

  • 1. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F, Sotto JJ, Salmi LR, Ifrah N, Reiffers J.
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [Abstract] [Full Text] [Related]

  • 2. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, Hunault-Berger M, Recher C, Lioure B, Himberlin C, Escoffre-Barbe M, Berthou C, Lissandre S, Fegueux N, Cahn JY, Jourdan E, Dreyfus F, Reiffers J, Milpied N, Ifrah N.
    J Clin Oncol; 2010 Jun 20; 28(18):3028-34. PubMed ID: 20479424
    [Abstract] [Full Text] [Related]

  • 3. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 4. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E.
    Leuk Res; 2005 Jun 15; 29(6):649-52. PubMed ID: 15863204
    [Abstract] [Full Text] [Related]

  • 5. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 6. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
    Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Martí JM, Bargay J, Guardia R, Juliá A, Granena A, Montserrat E, Sierra J, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias.
    Haematologica; 2004 Aug 15; 89(8):940-9. PubMed ID: 15339677
    [Abstract] [Full Text] [Related]

  • 7. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 15; 28(9):706-8. PubMed ID: 17274381
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.
    J Med Assoc Thai; 2009 Sep 15; 92(9):1143-9. PubMed ID: 19772172
    [Abstract] [Full Text] [Related]

  • 9. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.
    J Clin Oncol; 2006 Sep 20; 24(27):4499-506. PubMed ID: 16983120
    [Abstract] [Full Text] [Related]

  • 10. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J.
    Am J Hematol; 2009 Jul 20; 84(7):422-7. PubMed ID: 19484734
    [Abstract] [Full Text] [Related]

  • 11. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 20; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 12. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T, Arvanitopoulou E, Spanoudakis E, Kotsianidis I, Tsatalas K, Papaioannou M, Marinakis T, Skandali A, Viniou N, Yataganas X, Bakiri M.
    Ann Hematol; 2006 Apr 20; 85(4):250-6. PubMed ID: 16416114
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E.
    Hematol Oncol; 2004 Jun 20; 22(2):43-53. PubMed ID: 15386563
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
    Kim I, Koh Y, Yoon SS, Park S, Kim BK, Kim DY, Lee JH, Lee KH, Cheong JW, Lee HK, Kim SH, Kim H, Joo YD, Lee SM, Won JH, Park SK, Hong DS, Kim SH, Sohn SK, Kim CS, Park E, Kim MK, Park MR, Lee JH, Min YH, Korean Society of Hematology AML/MDS working party.
    Am J Hematol; 2013 Jan 20; 88(1):10-5. PubMed ID: 23077109
    [Abstract] [Full Text] [Related]

  • 15. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM.
    Semin Hematol; 1996 Oct 20; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [Abstract] [Full Text] [Related]

  • 16. Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial.
    Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lübbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A.
    Ann Hematol; 2004 Jun 20; 83(6):336-44. PubMed ID: 15034758
    [Abstract] [Full Text] [Related]

  • 17. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
    Ruutu T, Koivunen E, Nousiainen T, Pelliniemi TT, Almqvist A, Anttila P, Jantunen E, Koistinen P, Koponen A, Mikkola M, Oksanen K, Pulli T, Remes K, Sarkkinen R, Silvennoinen R, Timonen T, Vanhatalo S, Elonen E, Finnish Leukaemia Group.
    Eur J Haematol; 2004 Jan 20; 72(1):38-44. PubMed ID: 14962261
    [Abstract] [Full Text] [Related]

  • 18. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
    Olivieri A, Capelli D, Troiani E, Poloni A, Montanari M, Offidani M, Discepoli G, Leoni P.
    Exp Hematol; 2007 Jul 20; 35(7):1074-82. PubMed ID: 17588476
    [Abstract] [Full Text] [Related]

  • 19. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.
    Cancer; 2008 Nov 01; 113(9):2504-11. PubMed ID: 18825661
    [Abstract] [Full Text] [Related]

  • 20. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 01; 26(12):705-9. PubMed ID: 16620570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.